Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

Download Cerba Research's new report to discover how to overcome immunogenicity and safety challenges in oncology.

Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations Henlius to receive $31 million upfront, and up to $270 million in ...

TNF Indicates Likelihood of Patient Response to Costly IBD Treatment Before Initiation of Therapy SAN DIEGO, CA / ACCESS ...

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.

What’s on the horizon for pharmacy benefits this year, and how might these shifts reshape the way employers think about cost ...

Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.

Biocon Biologics Ltd receives positive CHMP opinions for denosumab biosimilars Vevzuo and Denosumab BBL, advancing bone ...

Aurobindo Pharma Ltd ( ($IN:AUROPHARMA) ) just unveiled an update. CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received a positive ...

A Senate panel has advanced three sets of bipartisan bills purportedly aimed at reforming the intellectual property (IP) ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...